Stockscreener 앱 받기
3.12
0.00%
0.00
시간 외 거래:
3.12
전일 마감가:
$3.12
열려 있는:
$3.11
하루 거래량:
25.95M
Relative Volume:
2.88
시가총액:
$803.19M
수익:
$403.14M
순이익/손실:
$-22.68M
주가수익비율:
-14.89
EPS:
-0.2095
순현금흐름:
$-13.09M
1주 성능:
+63.35%
1개월 성능:
+19.54%
6개월 성능:
+6.12%
1년 성능:
+197.14%
1일 변동 폭
$3.11
$3.12
1주일 범위
$1.80
$3.14
52주 변동 폭
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.12 | 803.19M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Esperion to be acquired by ARCHIMED - The Pharma Letter
MSN Money - MSN
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
What's Going On With Esperion Therapeutics Stock On Monday? - Benzinga
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Penny Stocks To Watch TodayMay 2nd - MarketBeat
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
HC Wainwright & Co. downgrades Esperion Therapeutics (ESPR) - MSN
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Piper Sandler Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Archimed to take Esperion Therapeutics private in $1.1 billion deal - WHTC
Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next - TechStock²
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpShould You Buy? - MarketBeat
The Biotech Growth Trust plc Archimed to acquire Biog Portfolio Company, Esperion Therapeutics. - marketscreener.com
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion agrees to $1.1 billion ARCHIMED buyout - TipRanks
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - BioPharma Dive
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - ChartMill
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - Yahoo Finance
Cantor Fitzgerald Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
H.C. Wainwright Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Ann Arbor drugmaker to be acquired by French investor - Crain's Detroit Business
Archimed to Acquire Biotech Growth Trust Portfolio Co Esperion for $1 Billion - marketscreener.com
H.C. Wainwright cuts Esperion stock rating on Archimed buyout By Investing.com - Investing.com Canada
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by HC Wainwright to Neutral - MarketBeat
An unknown funds, managed by ArchiMed SAS entered into a definitive agreement to acquire Esperion Therapeutics, Inc.. - marketscreener.com
ESPR Rallies As Royalty Deal Fuels Corstasis Expansion - StocksToTrade
Archimed to acquire Esperion Therapeutics for $1 billion By Investing.com - Investing.com Canada
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
ESPR Stock In Focus As Royalty Deal Fuels Corstasis Acquisition - timothysykes.com
Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs - Stock Titan
Esperion Therapeutics: Board of Directors Has Unanimously Approved the Transaction >ESPR - Moomoo
ARCHIMED to acquire Esperion for up to $1.1 billion - Investing.com
Esperion Therapeutics to Be Acquired by ARCHIMED in Up to $1.1 Billion Transaction, Shareholders to Receive $3.16 Per Share in Cash - Quiver Quantitative
Esperion to be Acquired by ARCHIMED - The Manila Times
ARCHIMED to acquire Esperion for up to $1.1 billion By Investing.com - Investing.com Canada
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):